Online inquiry

IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14996MR)

This product GTTS-WQ14996MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Acute lymphocytic leukemia (ALL) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ14996MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7982MR IVTScrip™ mRNA-Anti-GHR, GX-H9(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GX-H9
GTTS-WQ5265MR IVTScrip™ mRNA-Anti-S, CB-6(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CB-6
GTTS-WQ12064MR IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MOR-00208
GTTS-WQ3553MR IVTScrip™ mRNA-Anti-MIF, BAX069(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BAX069
GTTS-WQ14250MR IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RG-7116
GTTS-WQ15275MR IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Theraloc
GTTS-WQ5297MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ881MR IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-181
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW